Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CVM 
CEL-SCI Corp (CVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: CVM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -26.63% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.91M USD | Price to earnings Ratio - | 1Y Target Price 240.02 |
Price to earnings Ratio - | 1Y Target Price 240.02 | ||
Volume (30-day avg) 329126 | Beta 0.26 | 52 Weeks Range 1.98 - 47.70 | Updated Date 06/18/2025 |
52 Weeks Range 1.98 - 47.70 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.86% | Return on Equity (TTM) -244.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15880388 | Price to Sales(TTM) 11797.42 |
Enterprise Value 15880388 | Price to Sales(TTM) 11797.42 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.71 | Shares Outstanding 3135020 | Shares Floating 2997739 |
Shares Outstanding 3135020 | Shares Floating 2997739 | ||
Percent Insiders 1.2 | Percent Institutions 5.07 |
Analyst Ratings
Rating 5 | Target Price 8 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CEL-SCI Corp
Company Overview
History and Background
CEL-SCI Corp, founded in 1983, is a biotechnology company focused on cancer immunotherapy. It primarily develops investigational immunotherapy treatments for cancer. The company's history is centered around the development and clinical trials of its lead product, Multikine.
Core Business Areas
- Immunotherapy Development: Focused on developing and commercializing immunotherapies for the treatment of cancer, primarily using its Multikine technology platform. This includes research, clinical trials, and regulatory submissions.
Leadership and Structure
CEL-SCI Corp's leadership includes Geert Kersten as CEO. The company operates with a structure typical of biotechnology firms, with departments focusing on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Multikine (Leukocyte Interleukin, Injection): Multikine is CEL-SCI Corp's lead investigational immunotherapy for the treatment of head and neck cancer. It has completed Phase 3 clinical trials. As an investigational product, it currently has no market share. Competitors include companies developing other head and neck cancer treatments such as Merck (Keytruda), Bristol Myers Squibb (Opdivo) and Erbitux.
Market Dynamics
Industry Overview
The biotechnology industry, specifically cancer immunotherapy, is highly competitive and rapidly evolving. There's growing interest in treatments that harness the body's immune system to fight cancer.
Positioning
CEL-SCI Corp is positioned as a company developing a novel immunotherapy for head and neck cancer. Its competitive advantage hinges on the success and differentiation of Multikine.
Total Addressable Market (TAM)
The global head and neck cancer therapeutics market is expected to reach billions of USD. CEL-SCI Corp's potential positioning within this TAM depends on Multikine's approval and adoption.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Completed Phase 3 clinical trials
- Experienced management team
Weaknesses
- Single product focus
- Dependence on regulatory approval
- History of operating losses
Opportunities
- Potential for regulatory approval of Multikine
- Expansion into other cancer indications
- Partnerships with larger pharmaceutical companies
Threats
- Failure to obtain regulatory approval
- Competition from established cancer therapies
- Clinical trial risks
Competitors and Market Share
Key Competitors
- MRK
- BMY
- LLY
- AZN
Competitive Landscape
CEL-SCI Corp faces intense competition from established pharmaceutical companies with approved cancer therapies. Its advantage depends on demonstrating superior efficacy and safety of Multikine.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: CEL-SCI Corp's historical growth has been characterized by research and development progress rather than revenue generation.
Future Projections: Future projections depend heavily on the regulatory approval and commercialization of Multikine. Analyst estimates vary significantly, reflecting the uncertainty surrounding the company's prospects.
Recent Initiatives: Recent strategic initiatives include focusing on regulatory submissions for Multikine and exploring potential partnerships.
Summary
CEL-SCI Corp is a high-risk, high-reward biotechnology company focused on developing Multikine, an immunotherapy for head and neck cancer. Its strength lies in its novel approach and completed Phase 3 trials, but it faces significant challenges related to regulatory approval and competition. The company's future hinges on the success of Multikine and its ability to secure partnerships and funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CEL-SCI Corp
Exchange NYSE MKT | Headquaters Vienna, VA, United States | ||
IPO Launch date 1987-01-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://cel-sci.com |
Full time employees - | Website https://cel-sci.com | ||
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.